Camurus AB (STO: CAMX), a Swedish science-led biopharmaceutical company, announced on Friday the initiation of the European roll-out of weekly and monthly Buvidal (buprenorphine prolonged release solution for subcutaneous injection), which is now available in Finland and Sweden.

The company said Buvidal is the first long-acting medication approved in the EU for the treatment of opioid dependence in adults and adolescents from 16 years of age. It added that for the first time, patients in Finland and Sweden will have access to a long-acting opioid dependence therapy that can improve treatment outcomes compared to daily sublingual treatment.

Buvidal is administered as a small volume injection under the skin and is designed to deliver buprenorphine at a controlled rate over weekly and monthly dosing intervals, thereby avoiding the burdens and risks of daily medication.

Also, Buvidal has been studied in a comprehensive clinical study programme, including two phase 3 studies, where it has demonstrated effective blockade of opioid drug -liking and suppression of withdrawal, craving and patient's use of illicit opioids.

Also, Camurus said its launch plans are on track and it will also have products available for patients in Germany, UK and Denmark within the coming weeks.

Camurus is committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions.